With budget supporting from Ministry of Economic Affairs (MOEA), Institute of Biotechnology and Pharmaceutical Research (IBPR) has identified a novel anti-cancer drug delivery system candidate, DBPR115, which IND application has been approved by TFDA and the Phase I clinical trial has been initiated in July, 2021.
DBPR115 is the conjugation of Zn(II)-dipicolylamine (Zn-DPA) to the anti-cancer drug through a proprietary linker design. This patented platform provides substantial increase of drug concentration at targeted tumor sites, increases therapeutic index of the anti-cancer drugs, reduces drug dosage and subsequently lessens adverse effects induced by the drug. Patent protections were filed in several territories, such as Taiwan, Patent Cooperation Treaty (PCT; in 15 countries), and the United States (US patent was issued in July 2016).
About IBPR of the NHRI
Institute of Biotechnology and Pharmaceutical Research of the NHRI is a mission-driven drug discovery and development engine with vertical and horizontal coordination and integration. For more information, visit https://ibpr.nhri.org.tw/en/ .